The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: A single institutional survey

被引：12

作者：

Velcheti, Vamsidhar ^{[1
]}

Viswanathan, Avinash

Govindan, Ramaswamy

机构：

[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2006年 / 1卷 / 05期

关键词：

D O I：

10.1097/01243894-200606000-00023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：501 / 501

页数：1

共 5 条

[1]

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial [J].

Kelly, K ;

Crowley, J ;

Bunn, PA ;

Presant, CA ;

Grevstad, PK ;

Mainpour, CM ;

Ramsey, SD ;

Wozniak, AJ ;

Weiss, GR ;

Moore, DF ;

Israel, VK ;

Livingston, RB ;

Gandara, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3210-3218

[2]

Revisions in the International System for Staging Lung Cancer [J].

Mountain, CF .

CHEST, 1997, 111 (06) :1710-1717

[3]

PAGE NC, 2002, P AN M AM SOC CLIN, V21, pA305

[4]

SANDLER AB, 2006, J CLIN ONCOL, V23, pLBA4

[5]

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].

Schiller, JH ;

Harrington, D ;

Belani, CP ;

Langer, C ;

Sandler, A ;

Krook, J ;

Zhu, JM ;

Johnson, DH .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :92-98

← 1 →